Definitive Contract HHSN272201400014C
Award Date
9/30/14
Potential Completion Date
9/29/21
Potential Value
$13M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Durham, NC 27705, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $19,829,599.29 definitive cost-no-fee contract to Duke University for a Nonhuman Primate Core Humoral Immunology Laboratory to support AIDS vaccine research and development. The contract has a period of performance through March 29, 2025 and does not have a set-aside designation. Duke University's Office of Research Administration Division is the prime contractor for this award, which appears to be...
This is a $28,098,860.50 Cost No Fee Definitive Contract awarded to Duke University by the National Institute of Allergy and Infectious Diseases (NIAID) for the NIAID Virology Quality Assurance (VQA) program. The contract has no set-aside designation. Under this contract, Duke University, a prominent private research university, will provide various research, laboratory, and quality assurance services to support NIAID's VQA program, which conducts medical research in areas such as virology and...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Duke University for the production of a protein called A. CON-ENV-03 140CF. The contract has a firm fixed price of $149,839.00 and was awarded on May 10, 2012, with a completion date of June 8, 2012. The contract was not set aside for any specific socioeconomic designation. Duke University, through its Office of Research...
This is a $6,178,859.14 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Duke University. The contract is for a "NONHUMAN PRIMATE CORE VIROLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT". This is a definitive, cost-no-fee contract with a period of performance through December 14, 2024. The contract was awarded on December 22, 2017 and does not have a set-aside...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a $21,659,151.36 definitive cost-no-fee contract to Duke University to support the "ADVANCED DEVELOPMENT OF A NEUTRALIZING ANTIBODY VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES." This contract, which does not have a set-aside designation, will run through September 18, 2026. Duke University's Office of Research Administration Division will serve as the prime contractor on this...
This is a federal contract award to Duke University, a private university and non-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS). The contract is a Delivery Order under the "Therapeutics Against Infectious Diseases Phase 1" indefinite delivery/indefinite quantity (IDIQ) contract vehicle, with a ceiling value of $212,814.70....
This $7,752,063.96 federal contract award to Duke University's Office of Research Administration Division is a delivery order issued under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery, indefinite quantity (IDIQ) contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The award has a period of performance ending on July 12, 2024 and is for vaccine and treatment evaluation work, which aligns with the...
This federal contract award, valued at $5,822,726.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Duke University. The contract is for the "ADJUVANT COMPARISON AND CHARACTERIZATION" project, which aims to compare multiple vaccine adjuvants using various vaccine and antigen platforms through comprehensive immune assessments. The contract does not have a set-aside designation. This contract is part of a broader NIAID program that seeks to...
This is a federal contract award to Duke University by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), a civilian agency. The award is a $3,190,344.25 delivery order under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery, indefinite quantity (IDIQ) contract. The contract is for clinical research and immunization safety assessment services related to vaccines and treatments for infectious diseases. This...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,281,164 cost-no-fee delivery order to Duke University's Office of Research Administration Division to conduct a Phase 1 clinical trial on therapeutics against infectious diseases. The order is part of a larger Therapeutics Against Infectious Diseases Phase 1 contract. No set-aside designation was used. Duke University is a private research university...